Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.
The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer.
MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012.
MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 13, 24 | -1.66 Decreased by -2.17 K% | -1.32 Decreased by -25.76% |
| Nov 9, 23 | 8.46 Increased by +7.15 K% | -2.12 Increased by +499.06% |
| Sep 26, 23 | -1.51 Decreased by -1.16 K% | -2.41 Increased by +37.34% |
| May 11, 23 | -2.32 Decreased by -3.21 K% | -2.87 Increased by +19.16% |
| Feb 9, 23 | 0.08 Increased by +260% | -0.15 Increased by +153.33% |
| Nov 14, 22 | -0.12 Decreased by -9.09% | -0.14 Increased by +14.29% |
| Sep 8, 22 | -0.12 Decreased by -140% | -0.19 Increased by +36.84% |
| May 23, 22 | -0.07 Increased by +75% | -0.18 Increased by +61.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0 Decreased by -100% | -11.06 M Decreased by -207.9% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 65.3 M Increased by +647.96% | 56.37 M Increased by +429.6% | Increased by +86.33% Increased by +144.07% |
| Jun 30, 23 | 1.46 M Decreased by -87.23% | -10.03 M Increased by +38.36% | Decreased by -688.33% Decreased by -382.92% |
| Mar 31, 23 | 5.89 M Decreased by -27.32% | -14.48 M Increased by +43.47% | Decreased by -245.76% Increased by +22.22% |
| Dec 31, 22 | 32.73 M Increased by +79.65% | 10.25 M Increased by +277.82% | Increased by +31.32% Increased by +198.98% |
| Sep 30, 22 | 8.73 M Decreased by -34.79% | -17.1 M Decreased by -43.97% | Decreased by -195.92% Decreased by -120.78% |
| Jun 30, 22 | 11.41 M Increased by +12.83% | -16.27 M Decreased by -184.62% | Decreased by -142.54% Decreased by -152.25% |
| Mar 31, 22 | 8.11 M Increased by +235.36% | -25.62 M Increased by +18.17% | Decreased by -315.97% Increased by +75.6% |